在自身免疫内耳疾病中使用infliximab:一个病例报告
Pauline Millan1, Kehinde O Sunmboye2
1Medicine University Hospitals of Leicester NHS Trust Leicester UK.
Clinical case reports
|February 17, 2025
概括
自免疫内耳疾病 (AIED) 可以导致波动性听力损失. 输注Infliximab有效地管理了一名患有性结肠炎二次性AIED的患者,稳定听力并改善UC症状.
科学领域:
- 免疫学 免疫学 免疫学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 胃肠病学 胃肠病学
背景情况:
- 自免疫内耳疾病 (AIED) 呈现为双边,不对称,波动的感觉神经听力损失 (SNHL).
- 由于缺乏标准化标准和最终测试,对AIED的诊断具有挑战性.
- 皮质类固醇是主要的治疗方法,但长期疗效是有限的,皮质类固醇后的治疗方案并不完善.
研究的目的:
- 在患有性结肠炎 (UC) 的患者中报告二次AIED病例.
- 评估infliximab在治疗耐火AIED和并发UC的疗效.
- 突出生物治疗在AIED管理中的潜力.
主要方法:
- 一个病例报告,一名27岁的男性患有二次AIED和UC.
- 该患者接受了多种治疗,包括皮质类固醇,甲醇和阿扎西奥普林,但没有显著改善.
- 在AIED和UC两种情况下,启动了用infliximab输注的治疗.
主要成果:
- 患者在输液后经历了AIED和UC症状的改善.
- 听力在不需要口服皮质类固醇的情况下保持稳定.
- 没有临床或听力学改善被观察到与甲状腺酸盐或阿扎西奥普林.
结论:
- 因弗利西马布在治疗UC二次性AIED患者方面表现出有效性,导致症状改善和听力稳定.
- 生物疗法,如infliximab,可能是耐火AIED的可行选择.
- 进一步的大规模,多中心随机对照试验是必要的,以确认生物药物的有效性在AIED管理.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
110
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
110
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
135
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
135